Key result
Histamine pretreatment prevents doxorubicin-induced cardiac damage and enhances anti-tumor activity in animal models.
Why the study?
The potential protective effect of histamine on doxorubicin-induced hepatic and cardiac toxicity required evaluation in rodent models and triple-negative breast cancer models.
Does histamine prevent doxorubicin-induced hepatic and cardiac toxicity in rodent models?
Population
Male Sprague Dawley rats, Balb/c mice, and human MDA-MB-231 triple-negative breast tumor-bearing mice
Comparison
Control vs histamine vs Dox vs Dox+histamine
Design
Preclinical animal and in vitro/in vivo laboratory study
Follow-up
2 weeks
Authors
Loading...
Does not support clinical use; leaves open translation of histamine cytoprotection from rodent doxorubicin models to patients.
Does histamine prevent doxorubicin-induced hepatic and cardiac toxicity in rodent models?
Histamine demonstrates preclinical potential as a selective cytoprotective agent against doxorubicin-induced cardiotoxicity and hepatotoxicity without compromising anti-tumor efficacy.
Nicoud et al. (2015) studied Doxorubicin-induced hepatic and cardiac toxicity. Histamine vs. Doxorubicin alone or saline was evaluated on Cardiac and hepatic tissue toxicity and tumor growth. Pretreatment with histamine prevented doxorubicin-induced cardiac and hepatic tissue damage by reducing oxidative stress and apoptosis, while preserving and enhancing the anti-tumor activity of doxorubicin in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: